To predict the optimal chemoprophylactic dose of mefloquine in infants of 5-10 kg using physiologically based pharmacokinetic (PBPK) and clinical effectiveness models.
Introduction
Malaria is an important cause of infant morbidity and mortality in many African and other malaria-endemic countries, especially in young children lacking acquired immunity to the parasite, who are considered nonimmune [1] . Although malaria has been eradicated from the European region, imported cases remain a threat, with a significant burden of disease in countries such as the UK, France, Germany and Italy [2] . Between 15 and 20% of all imported malaria cases are in unprotected children from immigrant families visiting friends and relatives in endemic countries, with Plasmodium falciparum the dominant species [3, 4] . Chemoprophylaxis has a central role in protecting nonimmune travellers, with mefloquine having an evidence base for use in adults and children. The core data sheet (Lariam; F. Hoffmann-La Roche Ltd, Basel, Switzerland) reports a low oral clearance of around 2 l h -1 and subsequent long half-life of around 21 days allowing for weekly dosing. Common side effects include abdominal pain, diarrhoea, dizziness, headache, nausea, visual disturbances and neuropsychiatric reactions. In children, it is relatively well tolerated with fewer neurological adverse events reported compared to adults [5] [6] [7] [8] . Dosing of mefloquine is weightbased, and different national recommendations for children weighing <20 kg, typically either ¼ or ⅛ of a standard 250 mg tablet [6] ; the core data sheet version 6 for mefloquine (Lariam) active prior to undertaking this modelling work recommended a dose of ⅛ of a 250 mg tablet for infants weighing 5-10 kg, at odds with some national recommendations ( Table 1 ). The dosage of mefloquine for chemoprophylaxis should achieve an age independent minimum plasma concentration of 620 ng ml -1 , considered necessary to achieve 95% prophylactic efficacy across all age groups [9, 10] . While there are some pharmacokinetic (PK) data showing that clearance of the drug per kg is higher in children aged 6-24 months than in those aged 5-12 years [11] , there is a paucity of PK and clinical efficacy data available to address the question of which dose is likely to afford infants protective efficacy. This lack of clinical trial data can be addressed by: (i) PK simulation based on available clinical data [6] ; and (ii) dose optimization using established clinical effectiveness models and physiologically based PK (PBPK) models.
Toovey et al. constructed a model that estimated the clinical effectiveness of various chemoprophylactic antimalarials in the UK [12] . The model correctly predicted the number of malaria deaths, and provided a robust and reliable estimate of the number of imported malaria cases in the UK, giving a measure of the benefit derived from the use of any particular chemoprophylactic agent. The model was able to calculate the number of individuals who would need to be prescribed chemoprophylaxis to prevent one case of clinical malaria, and the protective efficacy of the recognized chemoprophylactic agents.
PBPK models marry the complex interplay of physiological parameters (demographics, organ sizes, blood flows etc.) with drug-related properties (lipid solubility, enzyme and transporter kinetics, etc.) and thus represent a mechanistic approach to predict quantitatively the PK of specific drugs in different populations [13] . Paediatric PBPK models additionally account for the development of organs and the ontogeny of specific enzymes and transporters that determine the age-related PK profiles [14] [15] [16] . In the case of mefloquine the elimination is predominantly via CYP3A4 [17] and a PBPK model can account for the known development of this enzyme.
The overall aim of this study is to develop a fit-for-purpose PBPK model for mefloquine, first verified against clinical PK data in adult and paediatric populations and then used to simulate the dose yielding therapeutically effective plasma concentrations in infants (5-10 kg). This dose was compared to the estimate from an established clinical effectiveness model [12] .
Methods

PBPK workflow
PBPK models were developed using the population-based PBPK software Simcyp (Simcyp Ltd, a Certara company, Sheffield, UK; version 14.1). The strategy for developing the mefloquine PBPK model followed the established best practice [18] , development, optimization and verification in an adult population followed by further verification in a paediatric population and then application to dose optimization in infants.
Development of the adult mefloquine PBPK model
Mefloquine drug-dependent input parameters are listed in Table 2 [17, [19] [20] [21] . Several published drug interaction studies as well as single-and multiple-dose PK studies were used in the compound file development stage; these are highlighted in Table 3a ,b [22] [23] [24] [25] [26] [27] [28] [29] .
Initial PK simulations of mefloquine in adults were performed using the Simcyp, North European Caucasian Healthy Volunteer and Chinese populations. The latter was used to represent the Thai population (see discussion).
The trial designs for the studies were replicated as closely as possible and the virtual trials were simulated 10 times. The fasted state Advanced Dissolution Absorption and Metabolism (ADAM) and full PBPK models were used. Initial simulations assumed 50% hepatic metabolism by CYP3A4 [47% overall metabolic fraction for CYP3A4 (fm CYP3A4 )], but due to uncertainty in some of the drug-drug interaction study results, 100% (95% overall fm CYP3A4 ) was also investigated.
Drug-drug interaction studies in adults.
Mefloquine-rifampicin. In this study performed in Thai subjects, 600 mg rifampicin, a strong CYP3A4 enzyme inducer, was given daily for 7 days, then twice weekly, and 500 mg mefloquine given on Day 7 as a single dose; the virtual Chinese healthy volunteer population implemented in Simcyp [32] was used in these simulations.
Mefloquine-ketoconazole. In this study performed in Thai subjects, ketoconazole 400 mg, a strong CYP3A4 inhibitor was given daily for 10 days and 500 mg mefloquine given on Day 5; the Chinese healthy volunteer population was used in these simulations.
Development and application of the paediatric PBPK mefloquine model
The final mefloquine model from the adult simulations with fm CYP3A4 set to either 47 or 95% was used for simulations Table 2 Input parameter values used to simulate the kinetics of mefloquine Calculated based on fu and glomerular filtration rate and also from 7% excreted unchanged in urine (reported range 1-9%, assumed 5% renal elimination) [21] (continues) Optimizing mefloquine dose in infants with Simcyp paediatric, which is based on a North European Caucasian population. The clinical studies used for the early verification of the paediatric model are shown in Table 3c [ 6, 11, 30, 31] . The weight range of interest for this study was 5-10 kg, which roughly translates to an age range of 2-18 months. Mefloquine is only licensed down to 5 kg and age 3 months, but for completeness an early infant age group of 2-3 months was included. To find optimal doses for different weight bands in infants to give equivalent exposure to 250 mg weekly in adults, a range of age bands representing a mean weight range from around 5.5 kg up to 10.8 kg were defined. These were, 2-3 months, 3-6 months, 6 months-1 year and 1 year-18 months. This was necessary since Simcyp does not allow the predefinition of weight ranges in a trial design. A detailed summary of the weight distribution within each age range is given in Table 4 .
The trial design was 10 trials of five individuals for each age range with the proportion of females fixed at 0.5. Simulations were run for multiple weekly doses for a total of 84 days and steady state results are presented for minimum plasma concentration (Cmin), maximum plasma concentration (Cmax) and area under the concentration-time curve to time t (AUC 0-t ). A variety of different scenarios were used in the dosing simulations to take into account the following factors:
• Uncertainty in the fraction of mefloquine metabolized by CYP3A4. fm CYP3A4 was set to 0.47 and 0.95. When an fm CYP3A4 of 0.47 was used, the other additional fraction eliminated in the liver was assumed to be independent of age (no ontogeny).
• The CYP3A4 ontogeny, the age profile from Salem et al. [33] and that recently published by Upreti and Wahlstrom [34] , were evaluated. These are shown in Supporting Information Figure S1 .
• Practical considerations lead to two doses of interest: these are 31.25 (⅛ tablet) and 62.5 mg (¼ tablet) weekly.
Data are presented geometric mean and confidence interval around the geometric mean and compared against an adult chemoprophylactic dose of 250 mg.
Application of the clinical effectiveness model
Detailed descriptions of the clinical effectiveness model and the drug utilization study have been provided elsewhere [12, 35] . Briefly, the clinical effectiveness model was constructed from real-world data comprising: World Tourism Organization reports on travellers from the UK arriving in countries with moderate or high malaria risk; results from a retrospective UK Clinical Practice Research Datalink study of chemoprophylactic drug utilization; information on chemoprophylaxis, case fatality and tolerability were derived from the travel medicine literature. The model was validated against UK Health Protection Agency data on imported malaria for 2007, being the most recent year for which temporally matched datasets were available. The Bloechliger et al. drug utilization study [35] was a descriptive study that interrogated the UK Clinical Practice Research Datalink, assessing the characteristics of individuals with a first-time antimalarial prescription for a recognized chemoprophylactic antimalarial, for the years 2001-2012.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/ BPS Guide to PHARMACOLOGY [36] .
Ethical approval
Data in the current study were derived from simulations and ethical approval was not required.
Results
Prediction of concentration-time profiles in adults using PBPK
The adult model could reasonably describe the concentration-time profile of mefloquine following single oral doses of between 250 ( Figure 1A ,B) [22, 23] and 1500 mg ( Figure 1C ) [24] compared with the observed data. On average the mean single-dose PK parameters were predicted within 2-fold of the observed values in the adult subjects, AUC and clearance (mean 1.1-fold, range 0.51 to 1.82-fold) and Cmax (mean 1.23-fold, range 0.64 to 2.41-fold). For the multiple 250 mg dose studies ( Figure 1D-F) [25] [26] [27] mean observed concentration time data was close to the predicted values. For the study by Mimica et al. [27] ( Figure 1E ) the clinical values are the Cmin values collected just prior to the next dose.
Prediction of drug-drug interactions in adults using PBPK Mefloquine-rifampicin. The adult PBPK model was reasonably able to describe the interaction between mefloquine and steady state rifampicin with the better prediction when the fm CYP3A4 was set at 0.95 of total elimination. The results showing the predicted concentration-time profiles both with and without inducer assuming an fm CYP3A4 of 0.47 and 0.95 are shown in Figure 2A ,B [29] . The observed and predicted AUC ratios for an fm CYP3A4 of 0.47 were 0.32 vs. 0.58, and for an fm CYP3A4 of 0.95 were 0.32 vs. 0.43, respectively. The observed and predicted Cmax ratios for an fm CYP3A4 of 0.47 were 0.81 vs. 0.89, and for an fm CYP3A4 of 0.95 were 0.81 vs. 0.84, respectively. Table 4 Summary of body weight distribution within each age range Mefloquine-ketoconazole. The simulation of the interaction between mefloquine and steady-state ketoconazole was more challenging and, using the specified trial design, was not predicted even when all of the hepatic metabolism was assigned to CYP3A4; the observed and predicted AUC 0-t and Cmax ratios were 1.80 vs. 1.24 and 1.64 vs. 1.06, respectively. The clinical data suggest a change in Cmax due to the inhibitor; but this was not picked up by the simulation, and could suggest that ketoconazole could be inhibiting one or more transporters and specifically intestinal P-glycoprotein (Pgp) efflux. The ketoconazole has a Ki value for inhibition of Pgp of around 0.67 μmol l -1 (Simcyp meta-analysis of literature; confidential data on file), and this was entered into the simulator along with a CL intT for efflux of mefloquine out of the enterocyte of 250 μl min -1
(estimated); the fm CYP3A4 was set as 0.95. This resulted in a slightly improved prediction of the interaction, the observed and predicted AUC 0-t and Cmax ratios were 1.81 vs. 1.34 and 1.64 vs. 1.26, respectively. The results of this simulation are shown in Figure 2C [28] .
The data suggest that the number of doses of ketoconazole after the mefloquine dose was mis-specified in the clinical study; assuming the continuous administration of the inhibitor postdose, the predicted AUC ratio (assuming no Pgp effect) is close to the observed value (1.77 vs. Simulations using the same settings applied to a similar study by Nosten et al. [31] , conducted in 12 Thai children aged 5-10 years, gave reasonable blood concentration-time profiles compared with the mean clinical data, although , respectively. No published clinical studies could be found that presented multiple dose plasma or blood concentration-time data in infants and children.
A further single-dose (25 mg kg -1 ) study was performed in 12 Thai infants aged 6 months to 2 years [11] . There are no observed data to compare against, but PK parameters are presented; the results from the different scenarios for fm CYP3A4 and ontogeny profile are shown in PBPK prediction of optimal dose in a paediatric population weighing 5-10 kg. These simulations were to investigate the most appropriate dose in infants to give equivalent exposure to 250 mg weekly in adults and achieve a Cmin concentration of 620 ng ml -1 .
The results for the Salem ontogeny profile for the different doses and fm CYP3A4 assumptions are shown for Cmax and Cmin in Figure 4 and for AUC 0-t in Supporting Information Figure S2 . The results in the 3-6-month and 6-months-1-year groups are most representative of the 5-10 kg weight range. For the lower 31.25 mg dose the predicted Cmin in the 12-18-month group is below the target when an fm CYP3A4 of 0.47 is assumed, and borderline when the fm CYP3A4 is assumed to be 0.95; otherwise, predicted Cmin are above 
Figure 4
Steady-state plasma minimum (grey diamond) and maximum (black diamond) concentrations in the different age bands following fixed doses of 31.25 or 62.5 mg weekly of mefloquine and assuming different metabolic fraction (fm) scenarios and the Salem ontogeny profile for CYP3A4; the adult dose is 250 mg weekly. The target chemoprophylactic/chemoprotective plasma concentration of 620 ng ml -1 is indicated on the plasma concentration graphs by dashed black line. All data are shown as geometric mean and geometric confidence interval
Optimizing mefloquine dose in infants the target in other age groups regardless of fm CYP3A4 assumption. The predicted Cmin concentrations were above the target in all age bands for the 62.5 mg dose, regardless of the assumed fm CYP3A4 . The higher dose would be needed in the 12-18-month age group. The Cmax concentrations were up to 4.31-fold higher in the 3-6-month age group compared with adults in the high-dose high fm CYP3A4 scenario. The results for the Upreti ontogeny profile for the different doses and CYP3A4 fm CYP3A4 assumptions are shown for Cmax and Cmin in Figure 5 and for AUC 0-t in Supporting Information Figure S3 . For the lower dose, the target concentration is only predicted to be reached in the 2-3-month age group, regardless of the fm CYP3A4 assumption. For the higher dose, the target concentration is predicted to be reached in all age bands, with the possible exception of the 12-18-month age group, which is borderline when the fm CYP3A4 is assumed to be 0.95 The Cmax concentrations were up to 2.42-fold higher in the 3-6-month age group compared with adults in the high-dose low fm CYP3A4 scenario.
Further analysis of all simulations in relation to individual data are shown in Table 6 . The percentage number of subjects with a plasma Cmin value <620 ng ml -1 for each of the scenarios is shown in bold, while the corresponding minimum value for any subject is shown alongside. Even at the higher dose of 62.5 mg with the Upreti ontogeny and high fm CYP3A4 there are 42% of 0.5-1-year-olds who are simulated not to achieve a Cmin value >620 ng ml -1 , this compares with an adult value of 52% following a 250 mg dose. When the Salem ontogeny is assumed, only 2% of subjects are predicted to have a Cmin value <620 ng ml -1 . These results could be partly explained due to some over-prediction of the variability within the model. 
Discussion
There are few mefloquine clinical PK data in infants to verify the optimal dose to achieve a minimum prophylactic target plasma concentration in the 5-10 kg weight band. This is reflected in the range of doses recommended by various national agencies; in general, the doses for children have been extrapolated from the recommended adult dose. Ideally a well conducted population PK study would be undertaken in a large cohort of paediatric subjects in order to confirm the optimal chemoprophylactic dose of this drug in this weight range. A previous simulation based on available PK data in the paediatric age group has suggested a loading dose of 125 mg followed by weekly doses of 62.5 mg in a 13.2 kg 3-year-old male would give a plasma Cmin concentration > 620 ng ml -1 [6] . In this study, two methods have been applied to further address this issue, a PBPK model to simulate the likely concentration-time data in this population and associated variability, and a clinical effectiveness model. To develop a PBPK model it was first necessary to resolve some of the areas of uncertainty, in relation both to drugrelated parameters, particularly the fm CYP3A4 of mefloquine, and also system-related parameters, specifically the ontogeny profile for CYP3A4 enzyme. The initial fm CYP3A4 was set at 0.47 of hepatic metabolism based on the observed 1.8-fold interaction with ketoconazole, fold interaction being approximately 1/(1 -fm). However, the drug-drug interaction simulations for mefloquine with ketoconazole and rifampicin both show improved predictions when assuming a higher fm CYP3A4 , and suggest that the fm CYP3A4 value is higher than 0.47 and could be a very high fraction (0.95) of total elimination. This is backed up by the data from the prediction of mefloquine in the 6-months-2-years age group (Table 5) [11] where an fm CYP3A4 of 0.95 gave the best prediction of AUC 0-t , Cmax and clearance, this suggests an influence of ontogeny on the remaining fraction metabolized compared to the scenario where fm CYP3A4 of 0.47 is assumed (no ontogeny on remaining fm).
There is still some uncertainty around the ontogeny of CYP3A4 at the early age bands and two different in vivoderived ontogeny profiles have been proposed [33, 34] . Comparing the performance of these models in the younger age groups (0.5-2 years) against CYP3A4 substrates used clinically in infants (intravenous midazolam and intravenous alfentanil, data not published) suggests that the Upreti model performs better, with less under-prediction of clearance. The Table 6 Analysis of the individual data for the different metabolic fraction (fm), dose and ontogeny scenarios showing % number of subjects with a minimum plasma concentration (Cmin) <620 ng ml -1 and also minimum value for worst-case individual
Age range (y)* fm
Upreti ontogeny Minimum (ng ml -1 ) % Cmin < 620 ng ml *Different fluid volume was given with the doses in different age group to reflect the likely reality in clinical practice: these were 20 ml in 2-3 months, 30 ml in 3-6 months, 50 ml in 6-12 months, and 100 ml in 12-18 months
Upreti model also seems to perform slightly better in predicting the observed value for oral clearance for mefloquine in 0.5-2-year-olds (Table 5 ) [11] . More research is needed in this area although this is currently constrained by lack of clinical data for specific CYP3A substrates across the paediatric age range. Depending on the assumptions made regarding ontogeny and to a lesser extent the fm CYP3A4, different conclusions can be made regarding the most suitable dose of 31.25 or 62.5 mg necessary to give similar exposure to 250 mg weekly in adults. Assuming that the fm CYP3A4 is high and that the Upreti ontogeny profile is most plausible in terms of the 5-10 kg population, a dose of 62.5 mg weekly will be needed in the 3-18-month age band to achieve a Cmin above the 620 ng ml -1 target concentration in the majority of infants. Only in the 2-3-month age group would the lower dose be indicated, but the minimum licensed age/weight for giving the drug is 3 months or >5 kg (core data sheet). This conclusion is in agreement with the current recommendations in the British National Formulary for Children for the 5-10 kg age range, but is against the V6 core data sheet dose; however, a new V7 Core Data sheet will include the recommended ¼ tablet dose (62.5 mg). The higher dose can also be justified based on the variability seen within paediatric age bands and the percentage of subjects within each band predicted not to achieve a Cmin < 620 ng ml -1 . The percentages failing to achieve target Cmin are much lower in the higher dose groups, but potentially still significant, depending on the assumption made regarding the CYP3A4 ontogeny. The Cmax and steady-state concentration should also be considered in terms of acceptability in regard to toxicity in this dose prediction exercise. In general the Cmax, but not Cmin, have been over-predicted for mefloquine in some paediatric subjects using the current model, and therefore predicted data most are likely to reflect the absolute worstcase scenarios; geometric means were 5702 ng ml -1 for a high dose high fm CYP3A4 assuming the Salem ontogeny and 3072 ng ml -1 high dose, low fm CYP3A4 assuming the Upreti ontogeny; these are compared against a value of 1300 ng ml -1 following multiple 250 mg weekly doses in adults. In terms of total exposure as measured by AUC, in the worst-case scenario for the 3-6-month age group following 62.5 mg was 2.2-fold (assuming Upreti ontogeny) higher than the exposure in adult population following a 250 mg dose. In a study of 102 infants weighing 5-12 kg who were administered a mefloquine treatment dose of 25 mg kg -1 dose [37] , no serious toxicity including major neuropsychiatric abnormalities were detected. However, vomiting was a problem but this was reduced by 40% by splitting the dose to 15 mg kg -1 followed by 10 mg kg -1 12 h later. Overall tolerability of mefloquine in relation to neurological adverse events appears to be better in small children (<20 kg) compared with adults [5] . Much of the tolerability data come from clinical studies on the treatment, rather than prophylaxis, of malaria; this again provides a margin of comfort that the higher preventative dose of 62.5 mg (maximum 12.5 mg kg -1 ) will be reasonably tolerated in the infant 5-10 kg group. One limitation of the current PBPK model is lack of true systems data to extrapolate between ethnic groups, although using the Chinese to represent the Thai population may be reasonable. No direct comparison on hepatic CYP3A4 was found between the two populations; however, they have reasonably close geographic proximity and many single nucleotide polymorphisms have been found to have similar frequencies in both [38] . Many of the studies used for model verification particularly in children were undertaken in a Thai population but the current model is mainly based on Caucasian data. Thus, the current predictions refer to this population; however, there is scope for future refinement of the model by developing specific paediatric ethnic populations e.g. Asian and African.
The oral absorption of mefloquine, including effects of formulation, was not considered in detail in the simulations, as the absorption phase appeared to be relatively rapid compared to the prolonged elimination and not to be significantly affecting the overall prediction of concentration-time profiles. Mefloquine may be a substrate for the transporter Pgp [39] involved in the intestinal efflux of the drug and including the effects of this transporter improved the prediction of the interaction with ketoconazole. However, the high concentrations of the drug in the gastrointestinal tract are likely to saturate the transporter, the drug is also a Pgp inhibitor. Hence Pgp effects on gastrointestinal absorption are unlikely to be clinically significant; this is in agreement with a recent study [40] and for this reason Pgp was not included in the final PBPK model. Another limitation was that the effects of food on the bioavailability of mefloquine were not considered and the fasted state was assumed; a high-fat breakfast has been shown to increase relative bioavailability by around 40% [41] . However, the core data sheet makes no recommendation regarding administration of mefloquine with food. One other potential limitation of the model is that no consideration was given to the two optical R and S isomers of mefloquine, for which some differences in metabolism may exist; however, the drug is marketed as a racemic mixture and no usable information was available on separate isomers.
Clinical trial data on the chemoprophylactic efficacy of the UK mefloquine regimen for children <20 kg are not available, a reflection of the drug's unusual development history. This has necessitated the examination of epidemiological data and the use of modelling to obtain estimates of efficacy. The use of two published sources, the Toovey et al. model [12] and the Bloechliger et al. drug utilization study [35] , enabled study of the efficacy of the currently recommended UK regimen in children aged 0-2 years, viz. 62.5 mg weekly.
The clinical effectiveness model provided results in line with those of the PBPK modelling, both supporting the 62.5 mg weekly dose for the age group of interest and providing a measure of mutual reassurance. Further support comes from analysis of UK national malaria incidence and mortality data. For 1993-2002, Stäger et al. [4] reported 351 cases of imported malaria in the UK in children aged 0-2 years, indicating malaria exposure, infection, and illness in the age group of interest over the period of study, and hence a need for effective chemoprophylaxis in this age group. Interestingly, Stäger et al. reported an absence of malaria-associated deaths in children aged ≤5 years over the 10-year period studied. Given the recognized lethality of malaria in this age group, the lack of mortality reflects the high standard of medical care in the UK. An additional factor in the absence of reported infant malaria deaths could be the use of chemoprophylaxis in British children travelling to malarious countries as, at least for 2007-2011, the Toovey et al. model [12] estimated that 120 cases of clinical malaria had been averted by the use of mefloquine chemoprophylaxis in children aged ≤2 years in the UK. Thus, mefloquine chemoprophylaxis at the UK's recommended dose significantly reduced the infant malaria burden. It is worth mentioning that, for 9 of the 10 years studied by Stäger et al. [4] , mefloquine was available for infant chemoprophylaxis in the UK.
The clinical effectiveness modelling suffers from the weaknesses inherent in all such modelling, and utilizes data from a number of different sources, although the model has undergone validation, and the drug utilization study reports real-world data. Additionally, this study cannot inform on the efficacy of other regimens, including the current German recommendation for children of 5-10 kg to use ⅛ of a standard 250 mg tablet per week, i.e. 31.25 mg weekly. A possible compensating factor for these weaknesses might be the inherent vulnerability to falciparum malaria of the age group studied, inasmuch as any lack of efficacy would be more likely to reveal itself in this age group.
In conclusion, although the results obtained using these methods cannot substitute for clinical trial data, the PBPK and clinical effectiveness modelling both support the UK's recommended dose of 62.5 mg weekly for malaria chemoprophylaxis in infants. The two analyses are mutually supportive, with the dual strategy adopted representing a novel approach to dose selection where conducting clinical trials would be problematic.
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http://onlinelibrary.wiley.com/doi/10.1111/bcp.13764/suppinfo Figure S1 Comparison of the Salem et al. [33] and Upreti et al. [34] ontogeny profiles for CYP3A4. Enzyme activity (intrinsic clearance) as determined from deconvolution from clinical data in each age group is expressed as a fraction of the adult value Figure S2 Steady state plasma area under the concentrationtime curve to time t in the different age bands following fixed doses of 31.25 or 62.5 mg weekly of mefloquine and assuming different metabolic fraction scenarios and the Salem ontogeny profile for CYP3A4; the adult dose is 250 mg weekly. The target chemoprophylactic/chemoprotective plasma concentration of 620 ng ml -1 is indicated on the plasma concentration graphs by a dashed black line. All data are shown as geometric mean and geometric confidence interval Figure S3 Steady state plasma area under the concentrationtime curve to time t in the different age bands following fixed doses of 31.25 or 62.5 mg weekly of mefloquine and assuming different metabolic fraction scenarios and the Upreti ontogeny profile for CYP3A4; the adult dose is 250 mg weekly.
The target chemoprophylactic/chemoprotective plasma concentration of 620 ng ml -1 is indicated on the plasma concentration graphs by a dashed black line. All data are shown as geometric mean and geometric confidence interval
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